Boron neutron capture therapy for glioblastoma multiforme: enhanced drug delivery and antitumor effect following blood-brain barrier disruption induced by focused ultrasound.

Abstract

AIM:

This study investigated whether the efficacy of boron neutron capture therapy was enhanced by means of intravenous administration of boronophenylalanine (BPA) with blood-brain barrier disruption induced by focused ultrasound (FUS).

MATERIALS & METHODS:

BPA was administered, followed by pulsed FUS, and the boron concentration in the treated brains was quantified by inductively coupled plasma mass spectroscopy. Growth of the firefly luciferase-labeled glioma cells was monitored through noninvasive biophotonic imaging. Finally, the brain tissue was histologically examined after sacrifice.

RESULTS:

Compared with the nonsonicated tumor group, animals treated with an injection of 500 mg/kg of BPA followed by FUS exhibited not only significantly increased accumulation of the drug at the sonicated tumor site, but also a significantly elevated tumor-to-normal brain drug ratio (p < 0.05).

DISCUSSION:

The data demonstrated that FUS significantly enhances the tumor-to-normal brain drug ratio in the sonicated tumor and subsequently the efficacy of boron neutron capture therapy.

• Authors: Feng-Yi Yang, Yi-Wei Chen, Fong-In Chou, Sang-Hue Yen, Yi-Li Lin, Tai-Tong Wong
• Journal: Future oncology (London, England) (Future Oncol) Vol. 8 Issue 10 Pg. 1361-9 (Oct 2012) ISSN: 1744-8301 [Electronic] England
• PMID: 23130933 (Publication Type: Journal Article)

Chemical References

• Phenylalanine

Topics

• Animals
• Blood-Brain Barrier (radiation effects)
• Boron Neutron Capture Therapy
• Brain Neoplasms (pathology, therapy)
• Drug Delivery Systems
• Glioblastoma (pathology, therapy)
• Humans
• Phenylalanine (administration & dosage, analogs & derivatives)
• Rats
• Sound
• Tissue Distribution